Navigation Links
Lilly, Kowa and Kowa Pharmaceuticals America Announce Co-Promotion and Licensing Agreement
Date:12/23/2009

INDIANAPOLIS and MONTGOMERY, Ala., Dec. 23 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY), Kowa Company, Limited, and Kowa's U.S. subsidiary, Kowa Pharmaceuticals America, Inc., today announced that Lilly and Kowa Pharmaceuticals America have entered into a co-promotion agreement in the United States to commercialize LIVALO® (pitavastatin). Lilly and Kowa have also entered into a licensing agreement in Latin America. LIVALO is a statin approved by the U.S. Food and Drug Administration (FDA) in August 2009 for the treatment of primary hyperlipidemia and mixed dyslipidemia.

Under the terms of the agreements, Kowa Pharmaceuticals America will receive an undisclosed upfront payment. Lilly and Kowa Pharmaceuticals America will co-promote LIVALO in the U.S. market, with both companies providing sales force resources and sharing development and marketing costs. Kowa Pharmaceuticals America will record all U.S. sales of LIVALO and will pay Lilly an escalating co-promotion fee based on the level of annual net sales. In addition, Lilly has acquired an exclusive license from Kowa to commercialize LIVALO in Latin American markets, including Mexico, Central America and South America. Additional deal terms were not disclosed.

"We are pleased to partner with Kowa to help bring this new statin to market and provide patients a new option to help control their cholesterol," said John Lechleiter, Ph.D., Lilly chairman and chief executive officer. "Our co-promotion arrangement in the U.S. and licensing arrangement in Latin America will allow Lilly to expand our product offerings in the cardiovascular therapeutic area and more efficiently utilize our existing cardiovascular sales force."

"Physicians are challenged by some patients who do not always do well on their current statin therapy, and who also mu
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... 2014   Easy Breathe , the fastest growing online ... Blog " - has received more than 4.5 million unique page ... are thrilled that so many people are finding our blog and ... Breathe. "We,re committed to making sleep apnea more widely known and ... about sleep apnea news , troubleshooting advice , and ...
(Date:8/20/2014)... YORK, Aug 20, 2014 Reportlinker.com announces ... in its catalogue: Global Patient Scales ... This report analyzes the worldwide markets for ... Product Segments: Floor Scales, Infant & Baby Scales, ... provides separate comprehensive analytics for the US, Canada, ...
(Date:8/20/2014)... SAN MARCOS, Texas , Aug. 20, 2014 ... purchase of five diverse sets of patent families ... and major innovation driver for Bayer AG of ... The patents acquired provide broad intellectual property ... achieved in economical high-volume quantum dot (QD) manufacturing. ...
Breaking Medicine Technology:Easy Breathe Blog Emerges as the Go-To Resource for Sleep Apnea Sufferers 2Easy Breathe Blog Emerges as the Go-To Resource for Sleep Apnea Sufferers 3Easy Breathe Blog Emerges as the Go-To Resource for Sleep Apnea Sufferers 4Global Patient Scales Industry 2Global Patient Scales Industry 3Global Patient Scales Industry 4Global Patient Scales Industry 5Global Patient Scales Industry 6Global Patient Scales Industry 7Global Patient Scales Industry 8Global Patient Scales Industry 9Global Patient Scales Industry 10Global Patient Scales Industry 11Global Patient Scales Industry 12Global Patient Scales Industry 13Global Patient Scales Industry 14Global Patient Scales Industry 15Global Patient Scales Industry 16Global Patient Scales Industry 17Global Patient Scales Industry 18Global Patient Scales Industry 19Quantum Materials Acquires Bayer Technology Services Quantum Dot Manufacturing and Quantum Dot Solar Cell Patents 2Quantum Materials Acquires Bayer Technology Services Quantum Dot Manufacturing and Quantum Dot Solar Cell Patents 3Quantum Materials Acquires Bayer Technology Services Quantum Dot Manufacturing and Quantum Dot Solar Cell Patents 4
... Inc. (OTC Bulletin Board: SCLR ) today ... and Drug Administration (FDA) identifying deficiencies regarding its Abbreviated ... The Company said the letter identified a number ... of the bioequivalence study submitted by SCOLR to support ...
... DIEGO, March 11, 2011 Conatus Pharmaceuticals Inc. today announced ... trial data of CTS-1027 for the treatment of hepatitis C ... Association for the Study of the Liver (EASL) to be ... 2011. Specifically, abstract 562 entitled: 24-WEEK TREATMENT WITH ...
Cached Medicine Technology:SCOLR Pharma, Inc. Receives Deficiency Letter from FDA on Pseudoephedrine Application 2Conatus Pharmaceuticals Will Display HCV Clinical Trial Data at the International Liver Congress™ (EASL) in March 2
(Date:8/21/2014)... August 21, 2014 While golfing in ... it hard to stay focused on his game due ... The constant whine, slapping and continual need to spray ... methods to stay protected from insects while golfing. He ... in the Financial Services/Investment Banking Industry, decided to change ...
(Date:8/21/2014)... Atlantic Information Services, Inc. (AIS) — industry-leading ... The AIS Report on Blue Cross & Blue Shield ... Association or its member companies) — is pleased to ... Management Insight Series. Bundled Payment Models: Bottom-Line Strategies ... — Horizon Healthcare Services, Inc. and Arkansas Blue Cross ...
(Date:8/21/2014)... San Diego, CA (PRWEB) August 21, 2014 ... website daily regarding all the latest information from the ... Solution . , The US FDA announced on August ... Peritoneal Dialysis Solution with 2.5% Dextrose 5000mL (Ambu-Flex II), ... to the presence of particulate matter. , The ...
(Date:8/21/2014)... Sometimes you have to lose the life of your dreams ... to a Hundred: Finding My Purpose through My Pain,” Jason Roy, ... broken family, a childhood of gang violence and two life-altering car ... to be,” Roy said. “I didn’t give up on God when ... today of helping others overcome their trials.” , He said his ...
(Date:8/21/2014)... August 21, 2014 OpsAssure, the ... start-ups selected to participate in the Harbor Accelerator's ... mentorship, curriculum sessions and valuable resources.he Harbor’s goal ... the region. Each start-up selected for the program ... order to help businesses grow quickly, test markets ...
Breaking Medicine News(10 mins):Health News:Financial VP Fights Pesky Bugs with Launch of Biteback Sports Insect Shield® Golf Apparel 2Health News:New AIS Report Highlights Two Case Studies of Bundled Payment Models 2Health News:Dianeal Low Calcium (2.5mEq/L) Peritoneal Dialysis Solution with 2.5% Dextrose 5000mL (Ambu-Flex II) Recalled: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Zero to a Hundred: True Story of Escaping Death to Meet Life 2
... , , OAKLAND, Calif. , Jan. 13 ... have responded in less than one day to the call by ... assistance to residents of earthquake devastated Haiti —leading the ... support these efforts with donations of funds to support travel costs ...
... ... ... 2010 -- Connextions Inc. today announced the appointment of Kenneth A. Burdick ... with an outstanding record of management and fiscal performance with the nation’s most respected ...
... , KIRKLAND, Wash. , Jan. 13 Long term ... Lifetime Television,s Balancing Act show. Denise Gott , the featured expert, ... term care for our loved ones. "Three in four will eventually need ... (LTCFP), one of America,s most experienced long term care insurance ...
... , ... the trusted leader in acne treatment for 15 years, today ... revolutionized the treatment of acne now enhanced with exclusive micro-crystal ... to penetrate even clogged pores quickly is the first change ...
... surgeons say , WEDNESDAY, Jan. 13 (HealthDay News) -- ... coaxed a donor trachea to grow its own network ... for months in the recipient,s arm. , The innovative ... trachea (windpipe), but it did so without the need ...
... treatment, researcher says, , WEDNESDAY, Jan. 13 (HealthDay News) -- ... turn cancerous. , At issue is how mutations occur in ... Jan. 13 in Nature , researchers report that cancer-causing ... , "The bad news is that it is much easier ...
Cached Medicine News:Health News:National Conference Call Thursday for 1,500 RN Volunteers for Haiti Relief Effort 2Health News:Veteran Health Insurance Senior Executive Joins Connextions Inc. Board of Directors 2Health News:Veteran Health Insurance Senior Executive Joins Connextions Inc. Board of Directors 3Health News:Long Term Care Insurance Expert Featured on Lifetime Television's Balancing Act Show 2Health News:Proactiv(R) Introduces New Micro-Crystal Technology and Unprecedented Customer Access to Expert Acne Treatment Advice 2Health News:Proactiv(R) Introduces New Micro-Crystal Technology and Unprecedented Customer Access to Expert Acne Treatment Advice 3Health News:Proactiv(R) Introduces New Micro-Crystal Technology and Unprecedented Customer Access to Expert Acne Treatment Advice 4Health News:Proactiv(R) Introduces New Micro-Crystal Technology and Unprecedented Customer Access to Expert Acne Treatment Advice 5Health News:Transplanted Trachea Grows Own Blood Supply in Patient's Arm 2Health News:Transplanted Trachea Grows Own Blood Supply in Patient's Arm 3
Angled 45 degree shafts 8 mm long with 1 x 2 teeth and 5 mm tying platform. Serrated handle with dull finish....
Heavy curved shafts with 2 x 2 teeth and crisscross serrated 6 mm tying platform. Serrated handle with polished finish....
Straight shafts with teeth and 6 mm crisscross serrated tying surfaces. Serrated handle with polished finish....
Straight shafts with 1 x 2 teeth and serrated handle with polished finish....
Medicine Products: